Clinical Trials Logo

Spinal Muscular Atrophy Type III clinical trials

View clinical trials related to Spinal Muscular Atrophy Type III.

Filter by:
  • None
  • Page 1

NCT ID: NCT06137612 Enrolling by invitation - Clinical trials for Spinal Muscular Atrophy Type II

Spinal Cord Gray Matter Imaging in Spinal Muscular Atrophy

Start date: August 17, 2020
Phase:
Study type: Observational

This study aims to measure the spinal cord gray matter in patients with spinal muscular atrophy (SMA) type II and III in comparison with age- and sex-matched healthy controls (HC) using rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging, a novel MRI (Magnetic Resonance Imaging) method. Patient and HC undergo MRI examinations, clinical/neurological (handheld dynamometry) and electrophysiological investigations (MUNIX, Motor Unit Number Index). Serum markers of neuro-axonal and astrocytic injury are also assessed.

NCT ID: NCT04042025 Active, not recruiting - SMA Clinical Trials

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.

NCT ID: NCT00439569 Terminated - Clinical trials for Spinal Muscular Atrophy Type II

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

NPTUNE01
Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy types II or III; and to determine if the drug has an effect on SMN mRNA and protein levels.